-
Mashup Score: 5The Uromigos - 2 year(s) ago
Striving to provide balanced, scientific content related to care of patients with GU malignancies. …
Source: The UromigosCategories: Latest Headlines, UrologyTweet
-
Mashup Score: 2Laurence Albiges on Renal Cell Carcinoma New Phase II Data on Cabozantinib and Checkpoint Inhibitor Therapy - The ASCO Post - 2 year(s) ago
2023 ASCO Genitourinary Cancers Symposium Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discusses interim results from the CaboPoint study, which evaluated cabozantinib as second-line treatment in patients with unresectable, locally advanced or metastatic renal cell carcinoma with a clear cell component. Disease in the study participants had progressed…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: New Phase II Data on Cabozantinib and Checkpoint Inhibitor Therapy https://t.co/BpvfEqe7b0 #kcsm #kidneycancer #RCC #oncology #GU23 @GustaveRoussy @AlbigesL
-
-
Mashup Score: 0Post-second-line systemic treatment for advanced RCC - 2 year(s) ago
Tian Zhang, MD, MHS, UT Southwestern Medical Center, Dallas, TX, comments on post-second-line systemic treatment for advanced renal cell carcinoma,…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
🎥 @TiansterZhang of @UTSWNews discusses post-second-line systemic treatment for advanced RCC Watch: 👉https://t.co/X7LWKOdZUU👈 @ASCO #GU23 #PCSM #BlcSM #kcsm #TSCsm #UroOnc #KidneyCancer
-
@brian_rini and @tompowles1 have launched a new website, https://t.co/xuol5uQxyO, featuring podcasts, videos, Uromigos Live annual meeting material and much more! Visit soon for #GU23 content. @montypal @shilpaonc @PGrivasMDPhD @neerajaiims @drenriquegrande @DrChoueiri https://t.co/HWobkb0R9G